🎤 Upcoming Biotech Conferences
Loading conferences...
Free public preview
Track infectious disease catalysts with approval-probability scores and free alerts.
Infectious Disease Biotech Pipeline: Antivirals, Vaccines & Anti-Infectives
Every infectious disease program BioRadar tracks across 17 public biotech companies — drug candidates, trial phases and upcoming FDA decisions. Updated automatically.
BioRadar is tracking 210 infectious disease drug programs across 17 public companies. The most active companies by program count are GILD, INO, ARWR, SPRO, IBRX.
210Drug programs
17Companies
46In Phase 3
0Upcoming FDA dates
Companies with infectious disease programs
Phase 3 infectious disease programs (46)
| Ticker | Drug | Indication |
|---|---|---|
| GILD | F/TAF | Pre-Exposure Prophylaxis of HIV-1 Infection |
| GILD | enfuvirtide | HIV Infections |
| GILD | lopinavir or efavirenz | HIV Infections |
| GILD | CLEVUDINE IN ASSOCIATION TENOFOVIR | HBe Negative Chronic Hepatitis B |
| GILD | F/TDF | Pre-Exposure Prophylaxis of HIV-1 Infection |
| GILD | Subcutaneous (SC) Lenacapavir (LEN) | Pre-Exposure Prophylaxis of HIV Infection |
| GILD | PTM F/TAF | Pre-Exposure Prophylaxis of HIV Infection |
| GILD | PTM F/TDF | Pre-Exposure Prophylaxis of HIV Infection |
| GILD | Oral Lenacapavir (LEN) | Pre-Exposure Prophylaxis of HIV Infection |
| GILD | PTM Oral LEN | Pre-Exposure Prophylaxis of HIV Infection |
| GILD | Lenacapavir Tablet | HIV Pre-exposure Prophylaxis |
| GILD | Lenacapavir Injection | HIV Pre-exposure Prophylaxis |
| GILD | Teropavimab | HIV Infections |
| GILD | Zinlirvimab | HIV Infections |
| GILD | Descovy or Truvada | HIV Infections |
| GILD | ISL/LEN | HIV-1-Infection |
| GILD | PTM B/F/TAF | HIV-1-infection |
| GILD | PTM ISL/LEN | HIV-1-infection |
| GILD | Antiretroviral Combinations | HIV-1-Infection |
| GILD | Lenacapavir | HIV Infections |
| GILD | HIV PrEP - choice of F/TDF, F/TAF, or CA | HIV Infection |
| GILD | STI PEP - Doxycycline as Doxy-PEP | HIV Infection |
| GILD | SBR | HIV-1-infection |
| GILD | Rilpivirine | HIV Infections |
| GILD | Cabotegravir | HIV Infections |
| GILD | L-AmB standard dose | Disseminated Histoplasma Capsulatum Infection |
| GILD | Single high dose of liposomal amphoteric | Disseminated Histoplasma Capsulatum Infection |
| GILD | TDF/FTC 300mg/200mg fixed-dose combinati | HIV/AIDS |
| GILD | TAF/FTC 25mg/200mg fixed-dose combinatio | HIV/AIDS |
| MIRM | Bulevirtide 2 mg and Brelovitug - 300 mg | Chronic Hepatitis D Infection |
| MIRM | Brelovitug 300 mg | Chronic Hepatitis D Infection |
| MIRM | Brelovitug 900 mg | Chronic Hepatitis D Infection |
| MIRM | Delayed Treatment with Brelovitug 300mg | Chronic Hepatitis D Infection |
| PYPD | D-PLEX | Surgical Site Infection |
| PYPD | Standard of Care (SoC) | Surgical Site Infection |
| SMMT | Vancomycin | Clostridioides Difficile Infection |
| SMMT | Ridinilazole | Clostridioides Difficile Infection |
| SPRO | Dummy Infusion | Urinary Tract Infection |
| SPRO | TBP-PI-HBr | Urinary Tract Infection |
| SPRO | Imipenem-cilastatin | Urinary Tract Infection |
Phase 2 infectious disease programs (59)
| Ticker | Drug | Indication |
|---|---|---|
| AIM | Alferon LDO | HIV Infections |
| AIM | poly I-poly C12U | HIV Seropositivity |
| ARWR | chlorpheniramine | Hepatitis B, Chronic |
| ARWR | ARC-520 | Hepatitis B |
| ARWR | entecavir | Chronic Hepatitis B |
| ARWR | tenofovir | Chronic Hepatitis B |
| ARWR | antihistamine | Hepatitis B |
| ARWR | ARC-520 Injection | Hepatitis B |
| ARWR | tenofovir disoproxil | Hepatitis B |
| ARWR | pegylated interferon alpha 2a | Hepatitis B |
| CORT | Miricorilant (Cohort A) | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant (Cohort B) | Nonalcoholic Steatohepatitis (NASH) |
| CRDL | Cannabidiol, pharmaceutically produced w | COVID-19 |
| GILD | Subcutaneous Lenacapavir | HIV-1-infection |
| GILD | Optimized Background Regimen (OBR) | HIV-1-infection |
| GILD | Oral Lenacapavir | HIV-1-infection |
| GILD | Bictegravir/emtricitabine/tenofovir alaf | HIV-1-Infection |
| GILD | Lenacapavir pacfosacil | HIV-1-Infection |
| GILD | Lepetegravir | HIV-1-Infection |
| GILD | Lepetegravir/Lenacapavir pacfosacil FDC | HIV-1-Infection |
| GILD | Atazanavir | HIV Infections |
| GILD | Tenofovir/emtricitabine | HIV Infections |
| GILD | TAF | Chronic Hepatitis B |
| GILD | emtricitabine / tenofovir disoproxil fum | HIV-2 Infection |
| GILD | B/F/TAF (Adult Strength) | HIV-1 Infection |
| GILD | B/F/TAF (TOS) | HIV-1 Infection |
| GILD | obeldesivir | RSV Infection |
| GILD | CAB LA | HIV Infections |
| GILD | TDF/FTC tablets | HIV Infections |
| GILD | Cabotegravir Oral Tablet | HIV Infections |
| GILD | B/F/TAF | HIV-1-infection |
| GILD | Antiretroviral Therapy | HIV-1 Infection |
| GILD | BIC/LEN FDC | HIV-1-infection |
| GILD | GS-3242 Injection | HIV-1-infection |
| GILD | GS-3242 Tablet | HIV-1-infection |
| GILD | Bictegravir | HIV-1-infection |
| GILD | efavirenz (drug) | HIV Infections |
| GILD | didanosine, ddI (drug) | HIV Infections |
| GILD | emtricitabine, FTC (drug) | HIV Infections |
| GILD | co-formulated 25mg TAF/ 200mg FTC | HIV Infections |
Phase 1 infectious disease programs (56)
| Ticker | Drug | Indication |
|---|---|---|
| AIM | Poly I:Poly C12U 50 ug | Influenza, Human |
| AIM | Poly I:Poly C12U 1250 ug | Influenza, Human |
| AIM | FluMist | Influenza, Human |
| AIM | Poly I:Poly C12U 200 ug | Influenza, Human |
| AIM | Poly I:Poly C12U 500 ug | Influenza, Human |
| ARWR | acetaminophen | Hepatitis B |
| ARWR | ARC-521 Injection | Hepatitis B |
| ARWR | JNJ-56136379 | Hepatitis B |
| ARWR | ARO-HBV | Hepatitis B |
| ARWR | ARO-HSD Injection | Non-alcoholic Steatohepatitis |
| CORT | Miricorilant 100 mg | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant 10 mg | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant 50 mg | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant 150 mg | Nonalcoholic Steatohepatitis (NASH) |
| GILD | 24 mg of nebulised 99mTc-liposomal ampho | Chronic Pulmonary Aspergillosis |
| GILD | 12 mg of nebulised 99mTc-liposomal ampho | Chronic Pulmonary Aspergillosis |
| GILD | GS-4321 | Chronic Hepatitis Delta |
| GILD | GS-3242 | HIV-1-infection |
| GILD | Standard of Care | HIV-1-infection |
| GILD | BVY | HIV-1-infection |
| GILD | GS-5423 | HIV-1-infection |
| GILD | MVA.tHIVconsv4 | HIV-1-infection |
| GILD | ChAdOx1.HIVconsv62 | HIV-1-infection |
| GILD | ChAdOx1.tHIVconsv1 | HIV-1-infection |
| GILD | MVA.tHIVconsv3 | HIV-1-infection |
| GILD | GS-2872 | HIV-1-infection |
| GILD | Vesatolimod (VES) | HIV-1-infection |
| GILD | GS-0415 | HIV -1 Infection |
| IBRX | 10-1074 | HIV Infection |
| IBRX | VRC07-523LS | HIV Infection |
| IBRX | EUA or approved vaccine | COVID-19 |
| IBRX | AAHI-SC3 Vaccine | COVID-19 |
| IBRX | AAHI-SC2 Vaccine | COVID-19 |
| IBRX | hAd5-S-Fusion+N-ETSD vaccine | Covid19 |
| INO | HCV DNA Vaccine INO-8000 | Chronic Hepatitis |
| INO | Rocakinogene Sifuplasmid | Chronic Hepatitis |
| INO | Electroporation-Mediated Plasmid DNA Vac | Chronic Hepatitis |
| INO | sD-NP-GT8 DNA | HIV Infections |
| INO | Alum | HIV Infections |
| INO | Trimer 4571 | HIV Infections |
Track infectious disease catalysts before they hit
BioRadar scores every upcoming FDA decision with an AI Probability of Approval, tracks cash runway and dilution risk, and sends free email alerts. Build a infectious disease watchlist in minutes.
Start free →
Data: ClinicalTrials.gov, SEC & FDA filings • Informational only, not investment advice. • All biotech stocks A–Z →